Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 4, 2006, Pages 373-379

  Gonzales Gay, Miguel A ^a   Garcia Unzueta, Maria T ^b   De Matias, Jose M ^a   Gonzalez Juanatey, Carlos ^a   Garcia Porrua, Carlos ^a   Sanchez Andrade, Amalia ^a   Martin, Javier ^a   Ilorca, Javier ^c  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Adhesion molecules; Anti TNF antibody infliximab; Atherosclerosis; Endothelial dysfunction; Inflammation; Rheumatoid arthritis; sICAM 3 and sP selectin

Indexed keywords

ANTIRHEUMATIC AGENT; CELL ADHESION MOLECULE; CHLOROQUINE; CYCLOSPORIN A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPAIN; STATISTICAL SIGNIFICANCE; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748519856     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
2. DEL RINCON I, ESCALANTE A: Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 278-86.
3. KUMEDA Y, INABA M, GOTO H et al.: Increased thickness of the arterial intimamedia detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-97.
4. PARK YB, AHN CW, CHOI HK et al.: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46: 1714-9.
5. GONZALEZ-JUANATEY C, LLORCA J, TESTA A, REVUELTA J, GARCIA-PORRUA C, GONZALEZ-GAY MA: Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-13.
6. SATTAR N, McCAREY DW, CAPELL H, McINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
7. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PINEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
8. VAUDO G, MARCHESI S, GERLI R et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63: 31-5.
9. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
10. IMPERATO AK, BINGHAM CO 3RD, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22: S108-14.
11. HÜRLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
12. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A, GARCIA-PORRUA C, LLORCA J, GONZALEZ-GAY MA: Active but transient improvement of endothelial function in long-term anti-tumor necrosis- antibody-infliximab treated rheumatoid arthritis patients. Arthritis Rheum 2004; 51: 447-50.
13. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C, GARCIA-PORRUA C, SANCHEZ-ANDRADE A, MARTIN J, LLORCA J: Anti-tumor necrosis factor- blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
14. KIORTSIS DN, MAVRIDIS AK, VASAKOS S, NIKAS SN, DROSOS AA: Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
15. PRADHAN A, RIFAI N, RIDKER P: Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-5.
16. RIDKER PM, HENNEKENS CH, ROITMAN-JOHNSON B et al.: Plasma concentrations of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 35: 88-92.
17. YOUNG J, LIBBY P, SHONBECK U: Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-67.
18. VEALE DJ, MAPLE C, KIRK G, McLAREN M, BELCH JJ: Soluble cell adhesion molecules - P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 1998; 27: 296-9.
19. ROMUK E, SKRZEP-POLOCZEK B, WOJCIECHOWSKA C et al.: Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest 2002; 32: 657-61.
20. RIDKER P, BURING JE, RIFAI N: Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 1336-42.
21. DESSEIN PH, JOFFE BI, SINGH S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-43.
22. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. VIS M, NURMOHAMED MT, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-5.
24. VAN GESTEL AM, STUCKI G: Evaluation of established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999; 13: 629-44.
25. BLAKE GJ, RIDKER PM: Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-71.
26. CUSH JJ, ROTHLEIN R, LINDSLEY HB, MAINOLFI EA, LIPSKY PE: Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098-102.
27. EL M, ASHOUR S, MOUSTAFA H, AHMED I: Altered levels of soluble adhesion molecules in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 2002; 29: 57-61.
28. WALLBERG-JONSSON S, CVETKOVIC JT, SUNDQVIST KG, LEFVERT AK, RANTAPAA-DAHLQVIST S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29: 875-82.
29. MAINI RN, BREEDVELD, FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
30. EL-GABALAWY H, GALLATIN M, VAZEUX R, PETERMAN G, WILKINS I: Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and non-rheumatoid synovium. Comparison with other adhesion molecules. Arthritis Rheum 1994; 37: 846-54.
31. CID MC, ESPARZA J, JUAN M et al.: Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in beta 1 and beta 2 integrin function. Eur J Immunol 1994; 24: 1377-82.
32. MARTIN S, RIECKMANN P, MELCHERS I et al.: Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. Immunol 1995; 154: 1951-5.